Treating Endothelial Disease With One Cornea Donor

Edward Holland, MD, chief medical advisor, discussed an injectable technique where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease.

This content originally appeared on our sister site, Ophthalmology Times.

OncLive spoke with Edward Holland, MD, chief medical advisor, Aurion Biotech, about the company's investigation of injectable endothelial cells, where one cornea donor could potentially supply hundreds of patients with treatment for endothelial disease as well as other forms of corneal edema.


Related Videos
Angela Genge, MD, FRCPC, eMBA, on Targeting STMN2 to Rescue Neurons in ALS
Peter Marks, MD, PhD
Jeffrey S. Chamberlain, PhD
Amer Beitinjaneh, MD, MSc, MPH, FACP, on Treating EBV+ PTLD With Tab-cel
Marco Davila, MD, PhD, on Investigating Mechanisms of CAR T Resistance in B-cell Malignancies
Chiraag Kapadia on Investigating Clonal Hematopoiesis After CAR T-cell Therapy
Related Content

ABCA4 Retinopathy Gene Therapy Demonstrates Efficacy in Preclinical Study

March 17th 2023

Around the Helix: Cell and Gene Therapy Company Updates – March 15, 2023

March 15th 2023

LHON Gene Therapy Continues to Show Efficacy and Safety at 3 Years Post-treatment

March 14th 2023

Gene Therapy May Improve Vision in XLRP, Further Research Needed

March 11th 2023

Around the Helix: Cell and Gene Therapy Company Updates – March 8, 2023

March 8th 2023

LHON-ND4 Gene Therapy Trial Completes Enrollment

March 6th 2023

ABCA4 Retinopathy Gene Therapy Demonstrates Efficacy in Preclinical Study

March 17th 2023

Around the Helix: Cell and Gene Therapy Company Updates – March 15, 2023

March 15th 2023

LHON Gene Therapy Continues to Show Efficacy and Safety at 3 Years Post-treatment

March 14th 2023

Gene Therapy May Improve Vision in XLRP, Further Research Needed

March 11th 2023

Around the Helix: Cell and Gene Therapy Company Updates – March 8, 2023

March 8th 2023

LHON-ND4 Gene Therapy Trial Completes Enrollment

March 6th 2023

ABCA4 Retinopathy Gene Therapy Demonstrates Efficacy in Preclinical Study

March 17th 2023

Around the Helix: Cell and Gene Therapy Company Updates – March 15, 2023

March 15th 2023

LHON Gene Therapy Continues to Show Efficacy and Safety at 3 Years Post-treatment

March 14th 2023

Gene Therapy May Improve Vision in XLRP, Further Research Needed

March 11th 2023

Around the Helix: Cell and Gene Therapy Company Updates – March 8, 2023

March 8th 2023

LHON-ND4 Gene Therapy Trial Completes Enrollment

March 6th 2023
© 2023 MJH Life Sciences

All rights reserved.